Role of Prolactin or Placental Lactogen in Mammary Tumor Development in Experimental Animals

  • Hiroshi Nagasawa


It is unequivocal that prolactin is a most important hormone in experimental mammary tumorigenesis. Besides prolactin acts directly on mammary glands, recent studies have evidenced that the hormone also participates in mammary tumor virus production and that some factors which influence mammary tumorigenesis, such as perinatal hormonal exposure, nutrition and immune mechanism, modulate the pituitary prolactin secretion. Placental lactogen is also shown to play a role similar to prolactin in mammary tumor development as well as in several biological phenomena. The primary objective of this chapter is to summarize a number of pertinent studies on these problems in experimental animals.


Unable to display preview. Download preview PDF.

Unable to display preview. Download preview PDF.


  1. 1.
    Bartley JC, Barber S, Abraham S. Rate of nucleic acid synthesis in mammary hyperplastic alveolar nodule outgrowths and transplanted adenocarcinomas in pregnant and lactating mice. Cancer Res 34: 2571–2575, 1974.PubMedGoogle Scholar
  2. 2.
    Bentvelzen P, Hilgers J. Murine mammary tumor virus. pp 311–355 in Viral Oncology, ed G Klein. Raven Press, New York, 1980.Google Scholar
  3. 3.
    Boyns AR, Buchan R, Cole EN, Forrest APM, Griffiths K. Basal prolactin blood levels in 3 strains of rats with differing incidence of 7,12-dimethylbenz(a)anthracene induced mammary tumours. Eur J Cancer 9: 169–171, 1973.CrossRefPubMedGoogle Scholar
  4. 4.
    Cave WT Jr, Dunn JT, MacLeod RM, Effect of iodine deficiency and high-fat diet on N-nitrosomethylureainduced mammary cancers in rats. Cancer Res 39: 729–734, 1979.PubMedGoogle Scholar
  5. 5.
    Chan PC, Cohen LA. Effect of dietary fat, antiestrogen and antiprolactin on the development of mammary tumors in rats. J Natl Cancer Inst 52: 25–30, 1974.CrossRefPubMedGoogle Scholar
  6. 6.
    Chan PC, Cohen LA. Dietary fat and growth promotion of rat mammary tumors. Cancer Res 35: 3384–3386, 1975.PubMedGoogle Scholar
  7. 7.
    Chan PC, Didato F, Cohen LA. High dietary fat, elevation of rat serum prolactin and mammary cancer. Proc Soc Exp Biol Med 149: 133–135, 1975.CrossRefPubMedGoogle Scholar
  8. 8.
    Chan PC, Head JF, Cohen LA, Wynder EL. Influence of dietary fat on the induction of mammary tumors by Nnitrosomethylurea associated hormone changes and differences between Sprague-Dawley and F344 rats. J Nati Cancer Inst 59: 1279–1283, 1975.CrossRefGoogle Scholar
  9. 9.
    Chen HJ, Bradley CJ, Meites J. Stimulation of growth of carcinogen-induced mammary cancers in rats by thyrotropin-releasing hormone. Cancer Res 37: 64–66, 1977.PubMedGoogle Scholar
  10. 10.
    Drosdowsky M, Edery M, Guggiari M, Montes-Rendon A, Rudali G, Vives C. Inhibition of prolactin-induced mammary cancer in C3Hf(XVII) mice with the trans isomer of bromotriphenylethylene. Cancer Res 40: 1674–1679, 1980.PubMedGoogle Scholar
  11. 11.
    Forsyth IA. The comparative study of placental lactogenic hormones: A review. pp 49–67 in Lactogenic Hormones, Fetal Nutrition, and Lactation, eds JB Josimovich, M Reynolds, E Cobo. Wiley & Sons, New York, 1974.Google Scholar
  12. 12.
    Furth J. The role of prolactin in mammary carcinogenesis. pp 233–248 in Human Prolactin, eds JL Pasteels, C Robyn. Am Elsevier Publ Co, New York, 1973.Google Scholar
  13. 13.
    Hawkins RA, Drewitt D, Freedman B, Killin E, Jenner DA, Cameron EHD. Plasma hormone levels and the incidence of carcinogen-induced mammary tumours in two strains of rat. Br J Cancer 34: 546–549, 1976.CrossRefPubMedPubMedCentralGoogle Scholar
  14. 14.
    Hilgers J, Bentvelzen P. Interaction between viral and genetic factors in murine mammary cancer. Adv Cancer Res 26: 143–195, 1978.CrossRefPubMedGoogle Scholar
  15. 15.
    Kerdellhue B, El Abed A. Inhibition of preovulatory gonadotropin secretion and stimulation of prolactin secretion by 7,12-dimethylbenz(a)anthracene in SpragueDawley rats. Cancer Res 39: 4700–4705, 1979.Google Scholar
  16. 16.
    Medina D. Preneoplasia in breast cancer. pp 47–102 in Breast Cancer Vol 2, ed WL McGuire. Plenum Pubi Corp, New York, 1978.Google Scholar
  17. 17.
    Mori T, Nagasawa H, Bern HA. Long-term effects of perinatal exposure to hormones on normal and neoplastic mammary growth in rodents: A review. J. Environ Path Toxicol 3: 191–205, 1980.Google Scholar
  18. 18.
    Nagasawa H. Mammary gland DNA synthesis as a limiting factor for mammary tumourigenesis (Forum). IRCS Med Sci 5: 405–408, 1977.Google Scholar
  19. 19.
    Nagasawa H. Causes of species difference in mammary tumourigenesis: Significance of mammary gland DNA synthesis. Med Hypotheses 5: 499–510, 1979.PubMedGoogle Scholar
  20. 20.
    Nagasawa H. Prolactin: Its role in the development of mammary tumours. Med Hypotheses 5: 1117–1121, 1979.CrossRefPubMedGoogle Scholar
  21. 21.
    Nagasawa H. Nutrition and breast cancer. IRCS Med Sci 8: 786–791, 1980.Google Scholar
  22. 22.
    Nagasawa H. Causes of age-dependency of mammary tumour induction by carcinogen in rats. Biometrics 34: 9–11 1981.Google Scholar
  23. 23.
    Nagasawa H, Morii S. Prophylaxis of spontaneous mammary tumorigenesis by temporal inhibition of prolactin secretion in rats at young ages. Cancer Res. 41: 1935–1937, 1981.PubMedGoogle Scholar
  24. 24.
    Nagasawa H, Mori T, Yanai R, Bern HA, Mills KT. Longterm effects of neonatal hormonal treatments on plasma prolactin levels in female BALB/cfC3H and BALB/c mice. Cancer Res 38: 942–945, 1978.PubMedGoogle Scholar
  25. 25.
    Nagasawa H, Vorherr H. Rat mammary deoxyribonucleic acid synthesis during the estrous cycle, pregnancy, and lactation in relation to mammary tumorigenesis. Am J Obstet Gynecol 127: 590–593, 1977.CrossRefPubMedGoogle Scholar
  26. 26.
    Nagasawa H, Yanai R. Effect of prolactin or growth hormone on growth of carcinogen-induced mammary tumors of adreno-ovariectomized rats. Int J Cancer 6: 488–495, 1970.CrossRefPubMedGoogle Scholar
  27. 27.
    Nagasawa H, Yanai R. Quantitative participation of placental mammotropic hormones in mammary development during pregnancy in mice. Endocrinol Jpn 18: 507–510, 1971.CrossRefPubMedGoogle Scholar
  28. 28.
    Nagasawa H, Yanai R. Effect of human placental lactogen on growth of carcinogen-induced mammary tumors in rats. Int J Cancer 11: 131–137, 1973.CrossRefPubMedGoogle Scholar
  29. 29.
    Nagasawa H, Yanai R. Some discrepancies between the use of DNA synthesis and wholemount preparations as indices of mammary gland response to pituitary mammotrophin. J Endocrinol 67: 303–304, 1975.CrossRefPubMedGoogle Scholar
  30. 30.
    Nagasawa H, Yanai R. Mammary nucleic acids and pituitary prolactin secretion during prolonged lactation in mice. J Endocrinol 70: 389–395, 1976.CrossRefPubMedGoogle Scholar
  31. 31.
    Nagasawa H, Yanai R. Effects of oestrogen and/or pituitary grafts on nucleic acid synthesis in the mammary glands of lactating mice. J Endocrinol 77: 319–323, 1978.CrossRefPubMedGoogle Scholar
  32. 32.
    Nagasawa H, Yanai R. Mammary gland prolactin receptor and pituitary prolactin secretion in lactating mice with different lactational performance. Acta Endocrinol (Kbh) 88: 94–98, 1978.CrossRefGoogle Scholar
  33. 33.
    Nagasawa H, Yanai R. Normal and abnormal growth of the mammary gland. pp 121–159 in Physiology of Mammary Glands, eds A Yokoyama, H Mizuno, H Nagasawa. Jap Sci Soc Press/Univ Park Press, Tokyo/Baltimore, 1978.Google Scholar
  34. 34.
    Nagasawa H, Yanai R. The in vitro mammary gland response to mammotropic hormones in mice with different mammary tumorigenesis. Eur J Cancer 17: 503–509, 1981.CrossRefPubMedGoogle Scholar
  35. 35.
    Nagasawa H, Yanai R, Azuma I. Suppression by Nocardia rubra cell wall skeleton of mammary DNA synthesis, plasma prolactin level, and spontaneous mammary tumori-genesis in mice. Cancer Res 38: 2160–2162, 1978.PubMedGoogle Scholar
  36. 36.
    Nagasawa H, Yanai R, Azuma I. Inhibitory effect of Nocardia rubra cell wall skeleton on carcinogen-induced mammary tumorigenesis in rats. Eur J Cancer 16: 389–393, 1980.CrossRefPubMedGoogle Scholar
  37. 37.
    Nagasawa H, Yanai R, Iwahashi H, Fujimoto M, Kuretani K. Difference in mammary gland susceptibility to prolactin between a high and a low mammary tumor strains of mice. Endocrinol Jpn 14: 351–356, 1967.CrossRefPubMedGoogle Scholar
  38. 38.
    Nagasawa H, Yanai R, Jones LA, Bern HA, Mills KT. Ovarian dependence of the stimulatory effect of neonatal hormone treatment on plasma levels of prolactin in female mice. J Endocrinol 79: 391–392, 1978.CrossRefPubMedGoogle Scholar
  39. 39.
    Nagasawa H, Yanai R, Nakajima Y. Response to adrenoovariectomy and/or pituitary grafting of carcinogen-induced mammary tumors in rats with different growth potential. Eur J Cancer 16: 1345–1350,. 1980.CrossRefPubMedGoogle Scholar
  40. 40.
    Nagasawa H, Yanai R, Taniguchi H. Importance of mammary gland DNA synthesis on carcinogen-induced mammary tumorigenesis in rats. Cancer Res 36: 2223–2226, 1976.PubMedGoogle Scholar
  41. 41.
    Nagasawa H, Yanai R, Taniguchi H. Reduction by pituitary grafts of mammary tumor age. Its variability in a high mammary tumor strain of mice. Effects of mammary DNA synthesis. Eur J Cancer 12: 1017–1019, 1976.CrossRefPubMedGoogle Scholar
  42. 42.
    Nagasawa H, Yanai R, Taniguchi H, Tokuzen R, Nakahara W. Two-way selection of Swiss albino mice for mammary tumorigenesis: Establishment of new two strains (SHN and SLN). J Natl Cancer Inst 57: 425–430, 1976.CrossRefPubMedGoogle Scholar
  43. 43.
    Nagasawa H, Yanai, R, Yamanouchi K. Inhibition of pituitary prolactin secretion by human placental lactogen in rats. J Endocrinol 71: 115–120, 1976.CrossRefPubMedGoogle Scholar
  44. 44.
    Nusse R, Michalides R, Boot LM, Röpcke G. Quantification of mouse mammary tumor virus structural protein in hormone induced mammary tumors of low mammary tumor mouse strains. Int J Cancer 25: 377–383, 1980.CrossRefPubMedGoogle Scholar
  45. 45.
    Reddy BS, Cohen LA, McCoy D, Hill P, Weisburger JH, Wynder EL. Nutrition and cancer. Adv Cancer Res 32: 237–345, 1980.CrossRefPubMedGoogle Scholar
  46. 45a.
    Rudali G, Vives CI, Guggiari M, Montes-Rendon A. Mammary carcinogenesis in (C3HxRIII)Fl mice which receive the trans isomer of a brominated triphenylethylene. Biomedicine 33: 126–128, 1980.PubMedGoogle Scholar
  47. 45b.
    Rudali G, Montes-.Rendon A, Asa R. Inhibition of mammary carcinogenesis of dimethylbenzanthracene treated rats with a brominated triphenylethylene. Biomedicine 31: 142–146, 1979.PubMedGoogle Scholar
  48. 46.
    Sasaki S,Iwami Y, Sano M. Strain-difference in prolactin cells of mouse anterior pituitary between high and low mammary tumor strains by stereological morphometry with an electron microscope. Okajimas Folia Anat Jpn 55: 341–350, 1979.CrossRefPubMedGoogle Scholar
  49. 47.
    Sinha YN, Baxter SR. Metabolism of prolactin in mice with a high incidence of mammary tumours: Evidence for greater conversion into a non-immunoassayable form. J Endocrinol 81: 299–314, 1979.CrossRefPubMedGoogle Scholar
  50. 48.
    Sinha YN, Salocks CB, Lewis UJ, VanderLaan WP. Influence of nursing on the release of prolactin and GH in mice with high and low incidence of mammary tumors. Endocrinology 95: 947–54, 1974.CrossRefPubMedGoogle Scholar
  51. 49.
    Sinha YN, Salocks CB, VanderLaan WP. Prolactin and growth hormone levels in different inbred strains of mice: Patterns in association with estrous cycle, time of day, and perphenazine stimulation. Endocrinology 97: 1112–1122, 1975.CrossRefPubMedGoogle Scholar
  52. 50.
    Sinha YN, Salocks CB, VanderLaan WP. Circulating levels of prolactin and growth hormone and natural incidence of mammary tumors in mice. J Toxicol Environ Health 1 (Suppl): 131–160, 1976.Google Scholar
  53. 51.
    Sinha YN, Selby FW, VanderLaan WP. The natural history of prolactin and GH secretion in mice with high and low incidence of mammary tumors. Endocrinology 94: 757–764, 1974.CrossRefPubMedGoogle Scholar
  54. 52.
    Sinha YN, Vlahakis G, VanderLaan WP. Serum, pituitary and urine concentrations of prolactin and growth hormone in eight strains of mice with varying incidence of mammary tumors. Int J Cancer 24: 430–437, 1979.CrossRefPubMedGoogle Scholar
  55. 53.
    Svec J, Hlavayova E, Matoska J, Thurzo V. Conditions for hormone-stimulated expression of endogenous C57B1 strain-associated mammary tumor virus genome. Neoplasma 28: 539–550, 1979.Google Scholar
  56. 54.
    Svec J, Links J. Mouse mammary tumor virus production stimulated by hormones and polyamines in cells grown in semisynthetic in vitro conditions. Int J Cancer 19: 249–257, 1977.CrossRefPubMedGoogle Scholar
  57. 55.
    Talamantes F, Ogren L, Markoff E, Woodard S, Phylogenetic distribution, regulation of secretion, and prolactinlike effects of placental lactogens. Fed Proc 39: 2582–2587, 1980.PubMedGoogle Scholar
  58. 56.
    Vorherr H. Breast Cancer pp 37–54. Urban-Schwarzenberg, Baltimore and Munnich, 1980.Google Scholar
  59. 57.
    Welsch CW. Prolactin and the development and progression of early neoplastic mammary gland lesions. Cancer Res 38: 4054–4058, 1978.PubMedGoogle Scholar
  60. 58.
    Welsch CW, Goodrich-Smith M, Brown CK, Wilson M. Inhibition of mammary tumorigenesis in GR mice with 2bromo-a-ergocryptine. Int J Cancer 24: 92–96, 1979.CrossRefPubMedGoogle Scholar
  61. 59.
    Welsch CW, Meites J, Prolactin and mammary carcinogenesis. pp 71–92 in Endocrine Control of Neoplasia, eds RK Sharma, WE Criss. Raven Press, New York, 1978.Google Scholar
  62. 60.
    Welsch CW and Nagasawa H. Prolactin and murine mammary tumorigenesis: A review. Cancer Res 37: 951–963, 1977.PubMedGoogle Scholar
  63. 61.
    Yanai R, Mori T, Nagasawa H. Long-term effects of prenatal and neonatal administration of 513-di,hydrotesto-sterone on normal and neoplastic mammary development in mice. Cancer Res 37: 4456–4459, 1977.PubMedGoogle Scholar
  64. 62.
    Yanai R, Nagasawa H. Mammary growth and placental mammotropin during pregnancy in mice with high or low lactational performance. J Dairy Sci 54: 906–910, 1971.CrossRefPubMedGoogle Scholar
  65. 63.
    Yanai R, Nagasawa H. Enhancement by pituitary isografts of mammary hyperplastic nodules in adreno-ovariectomized mice. J Natl Cancer Inst 46: 1251–1255, 1971.PubMedGoogle Scholar
  66. 64.
    Yanai R, Nagasawa H. Pituitary prolactin and growth hormone levels during different reproductive states in mice with a high and a low lactational performance. Horm Behav 2: 73–82, 1971.CrossRefGoogle Scholar
  67. 65.
    Yanai R, Nagasawa H. Inhibition of mammary tumorigenesis by ergot alkaloids and promotion of mammary tumori-genesis by pituitary grafts in adreno-ovariectomized mice. J Natl Cancer Inst 48: 715–719, 1972.PubMedGoogle Scholar
  68. 66.
    Yanai R, Nagasawa H. Enhancement by human placental lactogen of mammary hyperplastic nodules in ovariectomized mice. Cancer Res 33: 1642–1644, 1973.PubMedGoogle Scholar
  69. 67.
    Yanai R, Nagasawa H. Importance of progesterone in DNA synthesis of pregnancy-dependent mammary tumors in mice. Int J Cancer 18: 317–321, 1976.CrossRefPubMedGoogle Scholar
  70. 68.
    Yanai R, Nagasawa H. Development and growth of pregnancy-dependent and -independent mammary tumors in GR/A strain of mice and their interrelationship. Gann 69: 25–30, 1978.PubMedGoogle Scholar
  71. 69.
    Yang J, Enami J, Nandi S. Regulation of mammary tumor virus production by prolactin in BALB/cfC3H mouse mammary epithelial cells in vitro. Cancer Res 37: 3644–3647, 1977.PubMedGoogle Scholar
  72. 70.
    Yokoro K, Nakano M, Ito A, Nagao K, Kodama Y, Hamada K. Role of prolactin in rat mammary carcinogenesis: Detection of carcinogenicity of low-dose carcinogens and of persisting dormant cancer cell. J Natl Cancer Inst 58: 1777–1783, 1977.CrossRefPubMedGoogle Scholar
  73. 71.
    Yokoro K, Sumi C, Ito A, Hamada K, Kanda K, Kobayashi T. Mammary carcinogenic effect of low-dose fission radiation in Wistar/Furth rats and its dependency on prolactin. J Natl Cancer Inst 64: 1459–1466, 1980.CrossRefPubMedGoogle Scholar

Copyright information

© Eden Press Inc. 1982

Authors and Affiliations

  • Hiroshi Nagasawa

There are no affiliations available

Personalised recommendations